Blogs

6 June 2025

Accelerating LVV Process Development with Fast, Precise Titer Determination – Part 3

Rapid LVV Titer Determination with the Virus Counter Plus Platform  In Part One of this blog series, we introduced...

Read More

2 June 2025

Accelerating LVV Process Development with Fast, Precise Titer Determination – Part 2

Overcoming the Limitations of Current LVV Titer Measurement As described in Part One of this blog series, quantification of...

Read More

2 June 2025

Accelerating LVV Process Development with Fast, Precise Titer Determination – Part 1

Growing demand for lentiviral vectors (LVVs) is creating the need for robust, scalable, GMP manufacturing processes. Accelerating process development...

Read More

3 February 2025

Polo-like kinase inhibitors increase AAV production by halting cell cycle progression

Recombinant adeno-associated viruses (rAAVs) are commonly used in gene therapy for preclinical research and therapeutic applications. Despite the clinical...

Read More

1 February 2025

Recombinant AAV batch profiling by nanopore sequencing

Recombinant AAV vectors are widely used for in vivo gene therapy in all stages ranging from pre-clinical to clinical...

Read More

26 November 2024

The deep roots of gene therapy in Florida

Scientists have known about adeno-associated virus (AAV) for more than six decades. Researchers from around the world have been...

Read More

3 September 2024

Gene therapy CDMOs play critical role in enabling AAV process improvement & standardization

Wes McConnell, CFO at Ascend The approval of numerous gene and gene-modified cell therapies by regulatory agencies around the...

Read More

1 August 2024

Enhancing AAV production using high-throughput screens and rational design

Mo Mandegar, dPhil – Vice President and Head of Site, Alameda Adeno-associated viruses (AAVs) have emerged as a favored...

Read More

17 June 2024

The Importance of AAV Process Comparability Throughout Development

Relying on unscalable cell-culture processes during early stages can be fatal for product development. Markus Hörer, Chief Scientific Officer...

Read More